Saikosaponin B2
Based on 2 publication(s) in Google Scholar
Saikosaponin B2 is an antiviral and anticancer agent that regulates multiple transporters (such as various solute carriers and ATP-binding cassette transporters including MRP1, MRP2, and OCT2). Saikosaponin B2 is isolated from the plant glycoside component of the roots of Bupleurum scorzonerifolium. Saikosaponin B2 enhances the liver targeting of anticancer drugs via vinegar-baked Radix Bupleuri. Saikosaponin B2 inhibits HCV entry, replication, and translation, is effective against Daclatasvir (HY-10466)-resistant strains, and exerts a synergistic effect when used in combination with Daclatasvir. Saikosaponin B2 is commonly used in studies related to hepatocellular carcinoma and HCV infection.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.98%
- CAS No.: 58316-41-9
- 화학식: C42H68O13
- 분자량:780.98
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-N0249
Saikosaponin CMMP-2 Inducer -
HY-N0246
Saikosaponin AAnti-inflammatory Agent -
HY-15337
HesperidinAntioxidant -
HY-N0250
Saikosaponin DTriterpenoid Saponin -
HY-N0100
NaringeninFlavonoid -
HY-N0197
BaicalinAutophagy Inducer -
HY-N0148
RutinCBR1 Inhibitor -
HY-14393
EmodinNatural Anthraquinone -
HY-N0060
Ferulic acidFGFR1 Inhibitor -
HY-N0180
18β-Glycyrrhetinic acidEndogenous Metabolite -
HY-N2178
Saikosaponin FNatural Product -
HY-N0472
GeraniinTNF Receptor Inhibitor
Publications Citing Use of MedChemExpress (MCE) Saikosaponin B2
More
Biological Activity
제품 설명
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>80 μM
Compound: 8
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 26883148] |
| Bcap37 | IC50 |
>80 μM
Compound: 8
|
Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay
Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay
|
[PMID: 26883148] |
| Hep 3B2 | IC50 |
>80 μM
Compound: 8
|
Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
|
[PMID: 26883148] |
| HepG2 | IC50 |
35.1 μM
Compound: 8
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 26883148] |
| MCF7 | IC50 |
>80 μM
Compound: 8
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 26883148] |
| MRC5 | CC50 |
383 μM
Compound: 55
|
Cytotoxicity against human MRC5 cells incubated for 96 hrs by XTT assay
Cytotoxicity against human MRC5 cells incubated for 96 hrs by XTT assay
|
[PMID: 32845145] |
In Vitro
Saikosaponin B2 (0.128-128.0 μM; 48 h) exhibits low cytotoxicity in BRL3A and HEK293 cells, with >80% cell viability at concentrations up to 128.0 μM and 64.0 μM, respectively[1].
Saikosaponin B2 (64.0 μM; 24 h) inhibits MRP2 activity in MRP2-overexpressing HEK293 cells via reduction of MRP2 protein expression, leading to increased cisplatin accumulation[1].
Saikosaponin B2 (64.0 μM; 24 h) inhibits Pgp activity in Pgp-overexpressing HEK293 cells (without altering Pgp gene/protein expression), leading to increased rhodamine B accumulation[1].
Saikosaponin B2 (100 μM; 48 h) inhibits HCV polyprotein translation in pHCV-F.Luc-3′-UTR RNA-transfected Huh-7.5.1 cells by 37%[3].
Saikosaponin B2 (10-100 μM; 48 h) dose-dependently inhibits HCV RNA replication in Huh-7.5.1 cells stably expressing genotype 1b Con1 or 2a JFH1 replicons, with 55% and 71% reduction respectively at 100 μM[3].
Saikosaponin B2 (10-100 μM; 48 h) inhibits entry of genotype 1b Con1 and 2a JFH1 pseudotyped HCV into Huh-7.5.1 cells, with 78% inhibition at 10 μM for Con1 and 69% inhibition at 100 μM for JFH1[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BRL3A, HEK293
-
Concentration:0.128, 1.28, 6.4, 12.8, 25.6, 64.0, 128.0 μM
-
Incubation Time:48 h
-
Result:Maintained over 80% survival of BRL3A cells at concentrations up to 128.0 μM.
Maintained over 80% survival of HEK293 cells at concentrations up to 64.0 μM.
Chemical Information
-
CAS No. 58316-41-9
-
Appearance Solid
-
분자량 780.98
-
화학식 C42H68O13
-
Color White to off-white
-
SMILES
OC[C@@]1(C)[C@]2([H])CC[C@@]3(C)[C@]4(C)C[C@@H](O)[C@@]5(CO)CCC(C)(C)CC5=C4C=C[C@]3([H])[C@@]2(C)CC[C@@H]1O[C@]6([H])O[C@H](C)[C@H](O)[C@H](O[C@]7([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O
-
Structure Classification
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
High-throughput in vitro screening and in silico analysis for Zika virus inhibitor identification. [Abstract]2025 Nov 27. PMID: 41310171 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607
용액&용해도
In Vitro:
DMSO : 100 mg/mL (128.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
순도&문서
-
Data Sheet (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhao Y, et al. Saikosaponin b2 enhances the hepatotargeting effect of anticancer drugs through inhibition of multidrug resistance-associated drug transporters. Life Sci. 2019;231:116557. [Content Brief]
[2]. Fu R, et al. Effects of Animal Strain, Dose, and Cotreatment with Saikosaponin b2 on the Pharmacokinetics of Saikosaponin a in Rats. Eur J Drug Metab Pharmacokinet. 2019;44(6):827-836. [Content Brief]
[3]. Lee WP, et al. Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus. J Chin Med Assoc. 2019;82(5):368-374. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2804 mL | 6.4022 mL | 12.8044 mL | 32.0111 mL |
| 5 mM | 0.2561 mL | 1.2804 mL | 2.5609 mL | 6.4022 mL | |
| 10 mM | 0.1280 mL | 0.6402 mL | 1.2804 mL | 3.2011 mL | |
| 15 mM | 0.0854 mL | 0.4268 mL | 0.8536 mL | 2.1341 mL | |
| 20 mM | 0.0640 mL | 0.3201 mL | 0.6402 mL | 1.6006 mL | |
| 25 mM | 0.0512 mL | 0.2561 mL | 0.5122 mL | 1.2804 mL | |
| 30 mM | 0.0427 mL | 0.2134 mL | 0.4268 mL | 1.0670 mL | |
| 40 mM | 0.0320 mL | 0.1601 mL | 0.3201 mL | 0.8003 mL | |
| 50 mM | 0.0256 mL | 0.1280 mL | 0.2561 mL | 0.6402 mL | |
| 60 mM | 0.0213 mL | 0.1067 mL | 0.2134 mL | 0.5335 mL | |
| 80 mM | 0.0160 mL | 0.0800 mL | 0.1601 mL | 0.4001 mL | |
| 100 mM | 0.0128 mL | 0.0640 mL | 0.1280 mL | 0.3201 mL |
Saikosaponin B2 Related Classifications
HY-N0248 Related Classifications
Powered by Bioz